Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL): Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL) (NCT03207555), a na phase 2 study. The primary outcome is Participants With Complete Remission (CR) at 24 Months.

2. Clinical Question

The study addresses the timing of treatment in CLL/SLL: whether starting ibrutinib before symptoms develop is associated with complete remission at the stated assessment time. Its primary endpoint is a participant count, not a direct comparison of early treatment with observation. That distinction matters because the stated clinical motivation is comparative, while the registered design is single-group.

The registry record says 23 participants were registered on-study and 18 were evaluable for the primary outcome. It does not report the number who achieved complete remission. Therefore, the record does not provide the observed primary result or the precision of that result. The clinical question is identifiable, but the available outcome information does not answer it numerically.

3. Trial Design

This was a phase 2, open-label, single-group study sponsored by M.D. Anderson Cancer Center. The registry lists allocation as not applicable and masking as none. The intervention was ibrutinib, taken orally once daily for up to 2 years (24 cycles). The brief summary describes the study as taking place at MD Anderson.

The registry reports enrollment of 23 participants. Its brief summary says that up to 50 participants would be enrolled; the reported enrollment is the number registered on-study, not the planned maximum. The primary completion date was 2024-08-02, and the study status is completed. The registry also lists a start date of 2018-05-23.

There is no randomized allocation and no control arm in the registered design. Consequently, the study can describe outcomes among participants receiving ibrutinib, but it cannot directly estimate a randomized treatment contrast against waiting for symptoms to develop. Differences between the study experience and an external or historical group would not constitute a like-for-like randomized comparison.

The primary outcome is the count of participants with complete remission at 24 months, with a timeframe described as up to 24 months. The listed secondary outcomes are progression-free survival and overall response at 24 months. The registry lists four outcome measures overall, but reports no analysis entries. Statistical planning details for the trial itself, including a sample-size justification, are not reported in the registry record.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Analysis population for the primary outcome, as defined in the registry: Of the 23 participants registered on-study, 18 participants were evaluable.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Participants With Complete Remission (CR) at 24 Months, measured over Up to 24 months.

The primary endpoint is the number of participants with complete remission (CR) at 24 months. It is recorded as a participant count, so its basic interpretation is how many people in the stated assessment population met the remission definition. A count is not itself a rate: interpreting the proportion would also require a clearly specified denominator and the observed count.

The registry’s CR definition combines findings from several domains. It includes low peripheral blood lymphocytes, absence of significant lymphadenopathy on imaging, no hepatomegaly or splenomegaly, absence of constitutional symptoms, and specified blood-count findings without supportive treatment. It also requires bone marrow assessment with findings meeting the stated criteria. Thus, CR is a composite clinical assessment rather than a single laboratory measurement.

Using a defined endpoint allows the registry to specify what qualifies as remission rather than leaving the outcome to an unspecified judgment. The endpoint may describe disease status at the assessment time, but it does not by itself describe how long remission lasts or compare outcomes with an untreated group. The registry identifies 18 participants as evaluable for this endpoint, but the number meeting the CR definition is not reported in the registry record.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The statistical details can be understood by separating the outcome definition, the analysis population, the study design, and the uncertainty around an estimate. The registry gives some information about each, but does not report a completed statistical analysis for the primary endpoint.

What does a participant count convey?

The primary endpoint is a binary status at the participant level: each assessed participant either meets the registered CR definition or does not. The listed measure is the number of participants meeting that definition. A count is straightforward to describe, but its interpretation depends on the population being counted. A count alone does not express the fraction of the target population that might meet the definition, and it does not describe the uncertainty around that fraction.

For an interpretable proportion, both the number meeting the endpoint and the denominator used in the analysis need to be clear. The registry reports 18 evaluable participants among 23 registered on-study, but does not report the CR count. It also does not give further detail on how evaluability was determined or how participants without an evaluable outcome were handled. The posted information therefore does not support reconstruction of a primary endpoint estimate.

Why does the study design matter?

A single-group study observes outcomes under the intervention without a concurrent control group. It can describe what happened among the enrolled participants, subject to the completeness and quality of outcome assessment. It cannot, by design alone, distinguish the intervention’s effect from other explanations for those outcomes. Random allocation is one way clinical studies create a comparable control group; this record lists allocation as not applicable and masking as none.

The clinical question refers to earlier treatment versus waiting until symptoms develop. That comparison is not implemented as a randomized contrast in this study. Therefore, any outcome description from the ibrutinib group should not be presented as a direct estimate of the difference between those strategies.

What would uncertainty measures add?

General statistical explanation: a confidence interval expresses the range of values reasonably compatible with an estimate under the assumptions of the analysis. For a binary outcome, an interval around a proportion would convey how imprecisely the observed group result estimates the underlying proportion. A p-value addresses a statistical test under a specified null hypothesis and analysis plan; it does not measure the size or clinical importance of an effect.

The registry record does not report a confidence interval, p-value, or primary endpoint analysis. No precision claim or significance conclusion can be drawn from an outcome count that is itself absent. Even if an estimate were available, interpretation would need to account for the single-group design and the stated evaluable population.

What do the planning assumptions mean?

General statistical explanation: sample-size planning uses assumptions about the effect to detect, variability, significance level, allocation, and analysis method to illustrate the scale of a future study. These are design calculations, not outcomes observed in participants and not a measure of the probability that a completed study’s result is correct. The registry’s stated planning assumptions describe a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation, with the effect framed as a fraction of the observed effect. Those assumptions are not the registered single-group design, so any related planning illustration is hypothetical rather than a description of how this trial was designed.

For time-to-event outcomes, the stated planning convention is based on a total number of events; for other outcomes, it is expressed as participants per arm. This is a general distinction: event-driven planning depends on how many outcome events occur, while a participant-based calculation is framed around the number assigned to each group. The numerical planning illustrations and the trial’s own sample-size justification are not reported in the registry record. They should not be described as observed power.

How should over-dispersion and model choice be viewed?

General statistical explanation: over-dispersion occurs when count data vary more than a chosen model assumes. If ignored, estimated standard errors can be too small, making uncertainty appear narrower than it is. This consideration is relevant to some count outcomes, but the primary endpoint is a participant count for a binary CR status, and the registry does not report a model or an over-dispersion assessment. No specific modeling method can be attributed to the investigators.

The registry lists no analysis entries, and it does not report the statistical plan, inferential model, handling of missing outcomes, multiplicity procedure, or confidence-interval method. Statistical descriptions beyond the stated endpoint and planning assumptions would therefore be speculative.

10. Exact Estimates for Each Arm

No two-arm comparison is shown for this trial, but each arm's result can still be summarized with exact interval estimates computed from the posted counts. The Clopper-Pearson interval is exact and conservative; the Wilson interval is a common closer-to-nominal alternative; the Bayesian credible interval uses a uniform Beta(1, 1) prior. For small groups the three can differ noticeably.

R code and output

arm    <- c("Ibrutinib")
n      <- c(18)
events <- c(3)
for (i in seq_along(n)) {
  ci <- binom.test(events[i], n[i])$conf.int          # Clopper-Pearson exact interval
  cr <- qbeta(c(0.025, 0.975), 1 + events[i], 1 + n[i] - events[i])   # Bayesian, uniform Beta(1,1) prior
  wi <- (function(x, n) { p <- x / n; z <- qnorm(0.975); d <- 1 + z^2 / n
    c((p + z^2 / (2 * n) - z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d, (p + z^2 / (2 * n) + z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d) })(events[i], n[i])
  cat(sprintf("ARM|%s|%d|%d|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f\n", arm[i], n[i], events[i], 100 * events[i] / n[i],
              100 * ci[1], 100 * ci[2], 100 * wi[1], 100 * wi[2], 100 * cr[1], 100 * cr[2]))
}

ARM  Ibrutinib  18  3  16.7  3.6  41.4  5.8  39.2  6.1  39.6

11. Multiplicity, Missing Data and Analysis Populations

The registry lists four outcome measures overall, including complete remission at 24 months as the primary outcome and progression-free survival and overall response at 24 months as secondary outcomes. It reports zero analysis entries. Results for the listed outcomes and any associated inferential tests are not reported in the registry record.

When a study evaluates multiple outcomes or performs multiple statistical tests, the chance of at least one apparently notable result can increase. General statistical practice may address this through prespecified outcome hierarchies or multiplicity adjustments. Whether either approach was used in this study is not reported in the registry record. The number of listed outcome measures does not, by itself, establish how many tests were conducted.

The primary outcome population is described as 18 evaluable participants from 23 registered on-study. The registry does not state why some participants were not evaluable, how missing endpoint information was handled, or whether any imputation or sensitivity analysis was used. These details are not reported in the registry record. The available information also does not define an intention-to-treat analysis population or describe other analysis populations.

Without those details, the impact of missing outcome information cannot be assessed. An analysis limited to participants with evaluable outcomes can differ from an analysis that includes all registered participants, particularly if outcome availability is related to health status or response. The registry record does not provide enough information to determine whether such selection could affect the endpoint estimate.

12. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: neoplasms benign, malignant and unspecified (incl cysts and polyps) - other, specify (13.0%), infections and infestations - other, specify (8.7%), syncope (4.3%), blurred vision (4.3%).

The registry reports serious adverse events for the ibrutinib group, with 23 participants at risk and 6 affected. For other adverse events, it reports 23 participants at risk and 23 affected. The deaths field is 0. These are descriptive safety counts in the posted record, not estimates from a comparison with an untreated or randomized control group.

The record also lists selected serious-event terms and percentages: neoplasms benign, malignant and unspecified (including cysts and polyps), other, specify, at 13.0%; infections and infestations, other, specify, at 8.7%; syncope at 4.3%; and blurred vision at 4.3%. The percentages are reported as listed; the registry does not provide further detail in the registry record about event timing, recurrence, or causal attribution.

Serious adverse events and other adverse events are separate reporting categories. The counts do not indicate whether individual participants had more than one event, and they should not be added together. The record’s safety data describe what was reported during the study, but do not establish that ibrutinib caused a particular event or permit a comparative safety conclusion.

13. What the Result Does, and Does Not, Mean

The registry record establishes that a phase 2, single-group study evaluated daily oral ibrutinib in early-stage CLL/SLL participants described as having high-risk features but no treatment indications. It specifies complete remission at 24 months as the primary endpoint and identifies 18 participants as evaluable for that endpoint. It also records safety counts and selected serious adverse-event terms.

What the record does not establish is the observed number of participants with complete remission. Without that count, the primary outcome cannot be summarized as a response frequency, and its statistical precision cannot be assessed. The registry also does not report analyses for the secondary outcomes, confidence intervals, or p-values. It is therefore not possible to characterize the posted results as showing a particular degree of remission or to judge the uncertainty of an outcome estimate.

The single-group design means that observed outcomes cannot be interpreted as a direct comparison of early ibrutinib with waiting until symptoms develop. The clinical question motivated the research, but the study does not include a randomized control group to estimate that contrast. The record also does not report a statistical plan or enough detail about missing endpoint data to evaluate how those issues were handled.

The safety figures are descriptions of reported events among participants at risk. They do not show comparative risk, establish causation, or describe all possible safety outcomes. The absence of reported deaths in this record should be read as a recorded count, not as proof of no risk.

In short, the record describes a study design and outcome definitions, but does not post the primary efficacy result or the analyses needed for a fuller statistical interpretation. Conclusions should stay within those limits.

14. Why This Trial Matters Statistically

This study is statistically informative as an example of the difference between a clinical question and a design capable of directly answering it. The motivating question contrasts earlier treatment with waiting until symptoms develop. The registered study, however, is single-group, with no randomized comparator. That mismatch does not make the observations meaningless, but it defines what can be inferred: the design describes outcomes in the treated group rather than estimating a randomized contrast between strategies.

The endpoint also illustrates why a precise definition matters. Complete remission is defined through multiple clinical, laboratory, imaging, and bone marrow findings. A participant count based on that definition has a clear intended meaning, but interpretation still depends on knowing the observed count, the denominator, and the handling of participants without evaluable outcomes. The registry identifies 18 evaluable participants but does not post the remission count or explain the evaluability process.

Finally, a completed study record can contain important design and safety details while still lacking the statistical results needed to assess efficacy. The registry lists primary and secondary outcomes and reports adverse-event counts, but no analysis entries. For readers, this reinforces the distinction between a registered outcome and a reported outcome result. A protocol question, an endpoint definition, and a safety summary do not substitute for an estimate with uncertainty.

These features matter when assessing evidence: the analysis population, design, outcome reporting, and uncertainty all shape what conclusions are justified. Here, the available record supports a careful description of the trial, but not a numerical conclusion about the primary endpoint or a comparative treatment effect.

15. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The primary limitation is the absence of the primary outcome result in the registry record. Although complete remission at 24 months is defined and 18 participants are described as evaluable, the number meeting the definition is not reported. No endpoint estimate or uncertainty measure can be assessed.

The design is single-group and open-label, with allocation listed as not applicable and masking as none. There is no registered control arm to support a direct comparison with waiting until symptoms develop. The record does not report whether outcome assessment was independently reviewed or whether any other safeguards against assessment bias were used.

The difference between 23 participants registered on-study and 18 described as evaluable is not explained. Reasons for non-evaluability, missing-data methods, and the analysis population are not reported in the registry record. It is not possible to determine whether outcome availability could have influenced the primary analysis.

The registry lists secondary outcomes and four outcome measures overall, but reports no analysis entries. Multiplicity handling, statistical models, confidence intervals, p-values, interim analyses, and a statistical analysis plan are not reported in the registry record. The trial’s sample-size justification is also not reported; the listed planning assumptions are not a substitute for trial-specific design documentation.

Safety reporting is descriptive and lacks a randomized comparison. The listed counts and percentages do not establish attribution or comparative risk. The registry record also does not provide further event-level details in the registry record, such as timing or recurrence. These limitations restrict interpretation to the recorded study design and reported safety figures.

16. Related Tutorials

17. Related Statistical Calculators

18. Sources

• ClinicalTrials.gov: Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL) — NCT03207555.
• Registry record last updated 2025-09-02; status last verified 2025-08.
• Results first posted 2025-09-02.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

19. Record Summary

NCT03207555 is a completed phase 2, open-label, single-group study sponsored by M.D. Anderson Cancer Center. It enrolled 23 participants and evaluated oral ibrutinib taken daily for up to 2 years (24 cycles) in early-stage CLL/SLL without treatment indications but with high-risk features.

The primary outcome is the participant count with complete remission at 24 months. The registry says 18 participants were evaluable, but does not report the number who achieved remission. Progression-free survival and overall response at 24 months are listed as secondary outcomes; analysis results are not reported in the registry record.

The safety record reports 6 of 23 participants at risk with serious adverse events, 23 of 23 with other adverse events, and 0 deaths. The single-group design does not provide a randomized comparison with waiting until symptoms develop.